The “Catch-22” of aging: Our immune system protects us by committing our cells to die
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Dec-2025 11:11 ET (23-Dec-2025 16:11 GMT/UTC)
A team from Sun Yat-sen University Sun Yat-sen Memorial Hospital has identified a novel mechanism underlying platinum resistance in triple-negative breast cancer (TNBC): the circular RNA circSCAP encodes a 129-amino-acid protein (SCAP-129aa) that activates the PI3K/AKT pathway by stabilizing PIK3R2. Silencing circSCAP or combining platinum therapy with the PIK3R2 inhibitor significantly improved treatment efficacy in preclinical models, highlighting circSCAP and SCAP-129aa as potential biomarkers and therapeutic targets.
The study, published in PLoS Computational Biology, shows that the balance between two types of inhibition regulates how brain rhythms communicate, enabling flexible and efficient information routing. The research was carried out by the Institute for Cross-Disciplinary Physics and Complex Systems (IFISC UIB-CSIC), the Institute for Neurosciences (IN CSIC-UMH), and Aix-Marseille University (France).